Floatz logo

TACROLIMUS

Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)

Sumithira VasuSmall moleculePhase 3Dormant
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
55/ 100
Competitive Position
95/ 100

Competitive context

20 Active assets in the Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) cohort.

Asset / SponsorPhaseRating
Cytosin-Arabinosid
Associazione Italiana Ematologia Oncologia Pediatrica
Phase 4A
Vesanoid
The Affiliated People's Hospital of Ningbo University
Phase 4A
Idarubicine
Technische Universität Dresden
Phase 4A
Arsenic Trioxide
Quetzal Therapeutics
Phase 4BBB
Mitoxantrone
Technische Universität Dresden
Phase 4BBB

View all 50 →

Same molecule, other indications

TACROLIMUS is also rated in:

disease related to transplantationDormant
BBB
Indicative ·
79 / 100
View asset →
disease related to solid organ transplantationDormant
BBB
Indicative ·
76 / 100
View asset →
beta-thalassemia majorDormant
BBB
Indicative ·
75 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →